AZ’s Forxiga gets heart claim data on its EU labelAstraZeneca has been cleared to include cardiovascular and kidney outcomes data on the label of its type 2 Share XAZ’s Forxiga gets heart claim data on its EU labelhttps://pharmaphorum.com/news/azs-forxiga-gets-heart-claim-data-on-its-eu-label/
FDA fast-tracks Lilly/Boehringer’s Jardiance for heart failureEli Lilly and Boehringer Ingelheim’s Jardiance was the first diabetes drug to lower the risk of cardiovascular disease Share XFDA fast-tracks Lilly/Boehringer’s Jardiance for heart failurehttps://pharmaphorum.com/news/fda-fast-tracks-lilly-boehringers-jardiance-for-heart-failure/
FDA warns of genital gangrene risk with diabetes drug classThe US regulator released an official risk warning of a rare genital infection identified in 12 patients, including Share XFDA warns of genital gangrene risk with diabetes drug classhttps://pharmaphorum.com/news/risk-sglt2-inhibitors-fda-warns/
SGLT2 inhibitors: an emerging option for cardiologists?With studies showing potential for SGLT2 inhibitors in heart failure, a study of HCP online conversations reveals cardiologists Share XSGLT2 inhibitors: an emerging option for cardiologists?https://pharmaphorum.com/views-and-analysis/sglt2-inhibitors-cardiologists-option/
AZ’s diabetes combination Qtern approved in EuropeThe European Commission has granted marketing approval to a new combination pill from AstraZeneca to treat type 2 Share XAZ’s diabetes combination Qtern approved in Europehttps://pharmaphorum.com/transversal-categories/uk-and-europe/azs-diabetes-combination-qtern-approved-europe/
